CoChat

Current strategies against multidrug-resistant Staphylococcus aureus and advances toward future therapy

Kumar, Saurabh, Mahato, Richa Prasad, Ch, Sanjay, Kumbham, Soniya · 2025 · The Microbe
Cited by 68

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

Antimicrobial resistance (AMR) has emerged as a formidable challenge in the treatment of infectious diseases, posing significant risks to global health. This issue is particularly with Staphylococcus aureus , a bacterium that can become multidrug-resistant (MDR), leading to severe complications and systemic infections due to their complex characteristics and diverse virulence factors. These new developments of AMR in S. aureus affected the scientific community in discovering the next generation of antibiotics, in which only two classes of antibiotics for clinical use have been introduced in the past two decades. This stagnation highlights the urgency of addressing AMR and the increasing difficulty in combating infections caused by superbug strains of staphylococcus. To overcome the AMR challenges, there is an urgent need to investigate and develop alternate therapy acts through a new target mechanism. In this review, we have discussed in brief several novel strategies such as bacteriophages, and antimicrobial peptides (AMP) to combat these MRSA infections. Emerging strategies such as CRISPR-Cas systems which allow for precise genetic editing, monoclonal antibodies designed to target specific bacterial toxins, bacterial phage therapies, and nanomedicine applications nanomedicine applications have been thoroughly discussed. Other than synthetic derivatives, the application of plant-based derivates, and repurposing drugs that exhibit anti-microbial properties, have been summarized. In an overview, this review provides advanced targets for investigators to develop new treatment strategies against MDR to improve the therapeutic efficacy and compliance of patients. • Multidrug-resistant Staphylococcus aureus (MRSA) is a major global health threat, increasing morbidity, mortality, and costs. • Treatment options are limited due to evolving resistance mechanisms. • New therapies like bacteriophages and antibiotic combinations are needed. • Technologies such as CRISPR, monoclonal antibodies, and nanomedicine show promise. • Plant-derived compounds, drug repurposing, and new antibiotics offer potential solutions

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.microb.2025.100281

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 7 references

Research works printed but not linked: 122

  1. Abdallah, 2024, Staphylococcus aureus, Microb. Toxins Food Syst.: Causes Mech. Complicat., Metab., 235
  2. Abebe, 2023, Methicillin resistant Staphylococcus aureus: molecular mechanisms underlying drug resistance development and novel strategies to Combat, Infect. Drug Resist., 7641, 10.2147/IDR.S428103 · DOI · Paper page
  3. Adebisi, 2023, Balancing the risks and benefits of antibiotic use in a globalized world: the ethics of antimicrobial resistance, Glob. Health, 19, 27, 10.1186/s12992-023-00930-z · DOI
  4. Aide, M. (2023). "The Evolution of Sustainable Rice Production along the Lower Mississippi River (USA) with the Increasing Spector of Climate Change." · doi:10.5772/intechopen.112385
  5. Alaoui Mdarhri, 2022, Alternatives therapeutic approaches to conventional antibiotics: advantages, limitations and potential application in medicine, Antibiotics, 11, 1826, 10.3390/antibiotics11121826 · DOI · Paper page
  6. Aman, 2020, Nucleic acid detection using CRISPR/Cas biosensing technologies, ACS Synth. Biol., 9, 1226, 10.1021/acssynbio.9b00507 · DOI · Paper page
  7. Angelini, 2024, Plant-derived antimicrobials and their crucial role in combating antimicrobial resistance, Antibiotics, 13, 746, 10.3390/antibiotics13080746 · DOI · Paper page
  8. Anstead, G.M., J. Cadena and H. Javeri 2014. "Treatment of infections due to resistant Staphylococcus aureus." Methicillin-Resistant Staphylococcus aureus (MRSA) Protocols: 259-309. · DOI
  9. Anyaegbunam, 2022, The resurgence of phage-based therapy in the era of increasing antibiotic resistance: from research progress to challenges and prospects, Microbiol. Res., 264, 10.1016/j.micres.2022.127155 · DOI
  10. Baciu, 2024, The burden of antibiotic resistance of the main microorganisms causing infections in humans–review of the literature, J. Med. Life, 17, 246, 10.25122/jml-2023-0404 · DOI
  11. Bal, 2017, Future trends in the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infection: an in-depth review of newer antibiotics active against an enduring pathogen, J. Glob. Antimicrob. Resist., 10, 295, 10.1016/j.jgar.2017.05.019 · DOI
  12. Borges, 2015, Insights on antimicrobial resistance, biofilms and the use of phytochemicals as new antimicrobial agents, Curr. Med. Chem., 22, 2590, 10.2174/0929867322666150530210522 · DOI
  13. Bush, 2020, Epidemiology of β-lactamase-producing pathogens, Clin. Microbiol. Rev., 33, 10.1128/CMR.00047-19 · DOI · Paper page
  14. Ch, 2024, Cationized gelatin-sodium alginate polyelectrolyte nanoparticles encapsulating moxifloxacin as an eye drop to treat bacterial keratitis, Int. J. Biol. Macromol., 264, 10.1016/j.ijbiomac.2024.130457 · DOI
  15. Cheung, 2021, Pathogenicity and virulence of Staphylococcus aureus, Virulence, 12, 547, 10.1080/21505594.2021.1878688 · DOI · Paper page
  16. Chiu, 2016, Engineering antibody therapeutics, Curr. Opin. Struct. Biol., 38, 163, 10.1016/j.sbi.2016.07.012 · DOI · Paper page
  17. Coksu, 2024, Enhancing the treatment of Staphylococcus aureus infections: a nanosystem with including dual antimicrobial peptide, J. Drug Deliv. Sci. Technol., 97
  18. Cook, 2022, The past, present, and future of antibiotics, Sci. Transl. Med., 14, eabo7793, 10.1126/scitranslmed.abo7793 · DOI · Paper page
  19. Dale, 2018, Pharmacokinetics, tolerability, and safety of murepavadin, a novel antipseudomonal antibiotic, in subjects with mild, moderate, or severe renal function impairment, Antimicrob. Agents Chemother., 62, 10.1128/AAC.00490-18 · DOI
  20. Davies, 2003, Understanding biofilm resistance to antibacterial agents, Nat. Rev. Drug Discov., 2, 114, 10.1038/nrd1008 · DOI · Paper page
  21. Denardi, 2022, In vitro activity of the antimicrobial peptides h-Lf1-11, MSI-78, LL-37, fengycin 2B, and magainin-2 against clinically important bacteria, Braz. J. Microbiol., 1
  22. Duplessis, 2020, A review of topical phage therapy for chronically infected wounds and preparations for a randomized adaptive clinical trial evaluating topical phage therapy in chronically infected diabetic foot ulcers, Antibiotics, 9, 377, 10.3390/antibiotics9070377 · DOI
  23. Eckmann, 2010, Treatment of complicated skin and soft-tissue infections caused by resistant bacteria: value of linezolid, tigecycline, daptomycin and vancomycin, Eur. J. Med. Res., 15, 554, 10.1186/2047-783X-15-12-554 · DOI
  24. Escalona, 2024, Polymicrobial methicillin-resistant Staphylococcus aureus bloodstream infections, Microbiol. Spectr.: e01081-01024, 10.1128/spectrum.01081-24 · doi:10.1128/spectrum.01081-24
  25. Falagas, 2013, MRSA in Africa: filling the global map of antimicrobial resistance, PloS One, 8, 10.1371/journal.pone.0068024 · DOI · Paper page
  26. Fapohunda, 2022, CRISPR Cas system: a strategic approach in detection of nucleic acids, Microbiol. Res., 259, 10.1016/j.micres.2022.127000 · DOI
  27. Farid, 2023, Repurposing Amphotericin B: anti-microbial, molecular docking and molecular dynamics simulation studies suggest inhibition potential of Amphotericin B against MRSA, BMC Chem., 17, 67, 10.1186/s13065-023-00980-9 · DOI
  28. Fauconnier, A.J. E. r 2017. "Regulating phage therapy: the biological master file concept could help to overcome regulatory challenge of personalized medicines." 18(2): 198-200. · DOI
  29. Fernández, L., D. Gutiérrez, P. García and A.J. A. Rodríguez (2019). "The perfect bacteriophage for therapeutic applications—a quick guide." 8(3): 126. · DOI
  30. Fodor, 2020, Multidrug resistance (MDR) and collateral sensitivity in bacteria, with special attention to genetic and evolutionary aspects and to the perspectives of antimicrobial peptides—a review, Pathogens, 9, 522, 10.3390/pathogens9070522 · DOI
  31. Gajdács, 2019, The continuing threat of methicillin-resistant Staphylococcus aureus, Antibiotics, 8, 52, 10.3390/antibiotics8020052 · DOI · Paper page
  32. Gebreyohannes, 2019, Challenges of intervention, treatment, and antibiotic resistance of biofilm-forming microorganisms, Heliyon, 5, 10.1016/j.heliyon.2019.e02192 · DOI · Paper page
  33. Georgopapadakou, 1980, Penicillin-binding proteins in bacteria, Antimicrob. Agents Chemother., 18, 148, 10.1128/AAC.18.1.148 · DOI · Paper page
  34. Girolomoni, 2016, Fusidic acid betamethasone lipid cream, Int. J. Clin. Pract., 70, 4, 10.1111/ijcp.12808 · DOI
  35. Goodridge, 2010, Des. phage Ther., 11, 15
  36. Gopikrishnan, 2024, Emerging strategies and therapeutic innovations for combating drug resistance in Staphylococcus aureus strains: a comprehensive review, J. Basic Microbiol., 64, 2300579, 10.1002/jobm.202300579 · DOI
  37. Grooters, 2024, Strategies for combating antibiotic resistance in bacterial biofilms, Front. Cell. Infect. Microbiol., 14, 1352273, 10.3389/fcimb.2024.1352273 · DOI · Paper page
  38. Grygiel, 2024, Comprehensive approaches to combatting acinetobacter baumannii biofilms: from biofilm structure to phage-based therapies, Antibiotics, 13, 1064, 10.3390/antibiotics13111064 · DOI
  39. Heine, 2024, Anti-biofilm properties of laser-synthesized, ultrapure silver–gold-alloy nanoparticles against Staphylococcus aureus, Sci. Rep., 14, 3405, 10.1038/s41598-024-53782-x · DOI
  40. Henostroza, 2022, Antibiotic-loaded lipid-based nanocarrier: a promising strategy to overcome bacterial infection, Int. J. Pharm., 621
  41. Hu, 2016, Molecular events for promotion of vancomycin resistance in vancomycin intermediate Staphylococcus aureus, Front. Microbiol., 7, 1601, 10.3389/fmicb.2016.01601 · DOI · Paper page
  42. Jayalakshmi, 2021, A review on antimicrobial resistance, diagnosis and an alternative approach, J. Entomol. Zool. Stud., 9, 1058
  43. Jin, 2024, Exploring the role of bacterial virulence factors and host elements in septic arthritis: insights from animal models for innovative therapies, Front. Microbiol., 15, 1356982, 10.3389/fmicb.2024.1356982 · DOI
  44. Kandaswamy, 2024, Synergistic berberine chloride and curcumin-loaded nanofiber therapies against methicillin-resistant staphylococcus aureus infection: augmented immune and inflammatory responses in zebrafish wound healing, Int. Immunopharmacol., 140, 10.1016/j.intimp.2024.112856 · DOI
  45. Kang, 2015, Glycopeptide antibiotics: structure and mechanisms of action, J. Bacteriol. Virol., 45, 67, 10.4167/jbv.2015.45.2.67 · DOI · Paper page
  46. Khan, 2018, Current and future treatment options for community-associated MRSA infection, Expert Opin. Pharmacother., 19, 457, 10.1080/14656566.2018.1442826 · DOI
  47. Konreddy, 2019, Recent drug-repurposing-driven advances in the discovery of novel antibiotics, Curr. Med. Chem., 26, 5363, 10.2174/0929867325666180706101404 · DOI · Paper page
  48. Kumar, 2024, Multidrug-resistant sepsis: a critical healthcare challenge, Antibiotics, 13, 46, 10.3390/antibiotics13010046 · DOI · Paper page
  49. Lagacé-Wiens, 2012, Adverse reactions to β-lactam antimicrobials, Expert Opin. Drug Saf., 11, 381, 10.1517/14740338.2012.643866 · DOI · Paper page
  50. Laudano, 2011, Ceftaroline fosamil: a new broad-spectrum cephalosporin, J. Antimicrob. Chemother., 66, iii11
  51. Lazzaro, 2020, Antimicrobial peptides: application informed by evolution, Science, 368, eaau5480, 10.1126/science.aau5480 · DOI · Paper page
  52. Li, 2024, Biocompatible formulation of a hydrophobic antimicrobial peptide L30 through nanotechnology principles and its potential role in mouse pneumonia model infected with Staphylococcus aureus, Colloids Surf. B: Biointerfaces, 236, 10.1016/j.colsurfb.2024.113823 · DOI
  53. Li, 2020, Recent advances in zinc oxide nanostructures with antimicrobial activities, Int. J. Mol. Sci., 21, 8836, 10.3390/ijms21228836 · DOI · Paper page
  54. Linz, 2023, Clinical impact of Staphylococcus aureus skin and soft tissue infections, Antibiotics, 12, 557, 10.3390/antibiotics12030557 · DOI · Paper page
  55. Liu, 2024, Staphylococcus aureus infections and human intestinal microbiota, Pathogens, 13, 276, 10.3390/pathogens13040276 · DOI · Paper page
  56. Liu, 2022, Circular guide RNA for improved stability and CRISPR-Cas9 editing efficiency in vitro and in bacteria, ACS Synth. Biol., 12, 350, 10.1021/acssynbio.2c00381 · DOI
  57. Liu, 2021, Drug repurposing for next-generation combination therapies against multidrug-resistant bacteria, Theranostics, 11, 4910, 10.7150/thno.56205 · DOI · Paper page
  58. Magana, 2020, The value of antimicrobial peptides in the age of resistance, Lancet Infect. Dis., 20, e216, 10.1016/S1473-3099(20)30327-3 · DOI · Paper page
  59. Maher, 2024, Bacterial skin and soft tissue infections in older adults, Clin. Geriatr. Med., 40, 117, 10.1016/j.cger.2023.09.006 · DOI
  60. Mahey, 2021, Repurposing approved drugs as fluoroquinolone potentiators to overcome efflux pump resistance in Staphylococcus aureus, Microbiol. Spectr., 9, 10.1128/Spectrum.00951-21 · DOI
  61. Makvandi, 2020, Metal-based nanomaterials in biomedical applications: antimicrobial activity and cytotoxicity aspects, Adv. Funct. Mater., 30, 1910021, 10.1002/adfm.201910021 · DOI · Paper page
  62. Mba, 2022, Focus: antimicrobial resistance: antimicrobial peptides therapy: an emerging alternative for treating drug-resistant bacteria, Yale J. Biol. Med., 95, 445
  63. Mba, 2022, Antimicrobial resistance: revisiting the mechanisms of resistance, Microbiol. Soc.
  64. McLaughlin, 1981, Unique features in the ribosome binding site sequence of the gram-positive Staphylococcus aureus beta-lactamase gene, J. Biol. Chem., 256, 11283, 10.1016/S0021-9258(19)68589-3 · DOI · Paper page
  65. Merabishvili, M., C. Vervaet, J.-P. Pirnay, D.De Vos, G. Verbeken, J. Mast, N. Chanishvili and M.J. P. o Vaneechoutte (2013). "Stability of Staphylococcus aureus phage ISP after freeze-drying (lyophilization)." 8(7): e68797. · DOI · Paper page
  66. Milton, 2009, The EMEA guideline on first-in-human clinical trials and its impact on pharmaceutical development, Toxicol. Pathol., 37, 363, 10.1177/0192623309332997 · DOI · Paper page
  67. Mishra, 2017, Host defense antimicrobial peptides as antibiotics: design and application strategies, Curr. Opin. Chem. Biol., 38, 87, 10.1016/j.cbpa.2017.03.014 · DOI · Paper page
  68. Moazed, 1987, Chloramphenicol, erythromycin, carbomycin and vernamycin B protect overlapping sites in the peptidyl transferase region of 23S ribosomal RNA, Biochimie, 69, 879, 10.1016/0300-9084(87)90215-X · DOI · Paper page
  69. Moellering Jr, 1998, Antibiotic resistance: lessons for the future, Clin. Infect. Dis., 27, S135, 10.1086/514902 · doi:10.1086/514902
  70. Mondal, 2024, Antimicrobial nanoparticles: current landscape and future challenges, RSC Pharm., 10.1039/D4PM00032C · DOI · Paper page
  71. Morales-Durán, 2024, Unraveling resistance mechanisms in combination therapy: a comprehensive review of recent advances and future directions, Heliyon, 10.1016/j.heliyon.2024.e27984 · DOI
  72. Muteeb, 2023, Origin of antibiotics and antibiotic resistance, and their impacts on drug development: a narrative review, Pharmaceuticals, 16, 1615, 10.3390/ph16111615 · DOI · Paper page
  73. Olatunji, 2024, Next-generation strategies to combat antimicrobial resistance: integrating genomics, CRISPR, and novel therapeutics for effective treatment, Eng. Sci. Technol. J., 5, 2284, 10.51594/estj.v5i7.1344 · DOI
  74. Oliveira, 2019, Repurposing ibuprofen to control Staphylococcus aureus biofilms, Eur. J. Med. Chem., 166, 197, 10.1016/j.ejmech.2019.01.046 · DOI
  75. Oyama, 2022, In silico identification of two peptides with antibacterial activity against multidrug-resistant Staphylococcus aureus, npj Biofilms Micro, 8, 58, 10.1038/s41522-022-00320-0 · DOI
  76. Pal, 2024, Methicillin-resistant staphylococcus aureus (Mrsa) remains a major threat to public health, Am. J. Public Health, 12, 48
  77. Pal, 2024, Phage therapy: an alternative treatment modality for MDR bacterial infections, Infect. Dis., 56, 785, 10.1080/23744235.2024.2379492 · DOI
  78. Pan, 1999, Streptococcus pneumoniae DNA gyrase and topoisomerase IV: overexpression, purification, and differential inhibition by fluoroquinolones, Antimicrob. Agents Chemother., 43, 1129, 10.1128/AAC.43.5.1129 · DOI
  79. Park, 2017, Genetic engineering of a temperate phage-based delivery system for CRISPR/Cas9 antimicrobials against Staphylococcus aureus, Sci. Rep., 7, 44929, 10.1038/srep44929 · DOI · Paper page
  80. Pătrașcu, 2024, Skin lesions with loss of tissue and cutaneous-onset sepsis: the skin infection–sepsis relationship, Diagnostics, 14, 659, 10.3390/diagnostics14060659 · DOI
  81. Peters, 2012, Polymicrobial interactions: impact on pathogenesis and human disease, Clin. Microbiol. Rev., 25, 193, 10.1128/CMR.00013-11 · DOI · Paper page
  82. Pinho, 2024, Liposomal rifabutin—a promising antibiotic repurposing strategy against methicillin-resistant staphylococcus aureus infections, Pharmaceuticals, 17, 470, 10.3390/ph17040470 · DOI
  83. Pinilla, 2021, Lipid-based nanostructures for the delivery of natural antimicrobials, Molecules, 26, 3587, 10.3390/molecules26123587 · DOI
  84. Presta, 2005, Selection, design, and engineering of therapeutic antibodies, J. Allergy Clin. Immunol., 116, 731, 10.1016/j.jaci.2005.08.003 · DOI
  85. Ramdan, 2024, Influences of improper use of antibiotics on public health, البحوث التطبيقية في العلوم والانسانيات, 1, 41, 10.21608/aash.2024.375733 · doi:10.21608/aash.2024.375733
  86. Rangel-Vega, 2015, Drug repurposing as an alternative for the treatment of recalcitrant bacterial infections, Front. Microbiol., 6, 282, 10.3389/fmicb.2015.00282 · DOI · Paper page
  87. Rawat, 2023, Nanobiomaterials: exploring mechanistic roles in combating microbial infections and cancer, Discov. Nano, 18, 158, 10.1186/s11671-023-03946-x · DOI
  88. Rončević, 2019, Antimicrobial peptides as anti-infective agents in pre-post-antibiotic era?, Int. J. Mol. Sci., 20, 5713, 10.3390/ijms20225713 · DOI
  89. Sabath, 1982, Mechanisms of resistance to beta-lactam antibiotics in strains of Staphylococcus aureus, Ann. Intern. Med., 97, 339, 10.7326/0003-4819-97-3-339 · DOI · Paper page
  90. Sangiorgio, 2024, The impact of enterococcus spp. in the immunocompromised host: a comprehensive review, Pathogens, 13, 409, 10.3390/pathogens13050409 · DOI
  91. Şen Karaman, 2021, Recent advances in the use of mesoporous silica nanoparticles for the diagnosis of bacterial infections, Int. J. Nanomed., 6575, 10.2147/IJN.S273062 · DOI
  92. Shahid, 2009, Beta-lactams and beta-lactamase-inhibitors in current-or potential-clinical practice: a comprehensive update, Crit. Rev. Microbiol., 35, 81, 10.1080/10408410902733979 · DOI
  93. She, 2024, Lusutrombopag as a repurposing drug in combination with aminoglycosides against vancomycin-resistant enterococcus, ACS Infect. Dis., 10, 1327, 10.1021/acsinfecdis.3c00737 · DOI
  94. She, 2022, Repurposing eltrombopag as an antimicrobial agent against methicillin-resistant Staphylococcus aureus, Front. Microbiol., 12, 10.3389/fmicb.2021.790686 · DOI
  95. Shen, 2024, Affinity molecular assay for detecting Candida albicans using chitin affinity and RPA-CRISPR/Cas12a, Nat. Commun., 15, 9304, 10.1038/s41467-024-53693-5 · DOI
  96. Sher, 2024, Current state and novel outlook on prevention and treatment of rising antibiotic resistance in urinary tract infections, Pharmacol. Ther., 10.1016/j.pharmthera.2024.108688 · DOI
  97. Shi, 2022, The antimicrobial peptide LI14 combats multidrug-resistant bacterial infections, Commun. Biol., 5, 926, 10.1038/s42003-022-03899-4 · DOI
  98. Singh, S., A. Numan, H.H. Somaily, B. Gorain, S. Ranjan, K. Rilla, H.R. Siddique, P.J. M.S. Kesharwani and E. C (2021). "Nano-enabled strategies to combat methicillin-resistant Staphylococcus aureus." 129: 112384. · DOI
  99. Speziale, 2021, Monoclonal antibodies targeting surface-exposed and secreted proteins from staphylococci, Vaccines, 9, 459, 10.3390/vaccines9050459 · DOI · Paper page
  100. Tabaja, 2021, Epidemiology of methicillin-resistant Staphylococcus aureus in arab countries of the middle east and north African (MENA) region, Mediterr. J. Hematol. Infect. Dis., 13, 10.4084/MJHID.2021.050 · DOI
  101. Tarai, 2013, Recurrent challenges for clinicians: emergence of methicillin-resistant Staphylococcus aureus, vancomycin resistance, and current treatment options, J. Lab. Physicians, 5, 071, 10.4103/0974-2727.119843 · DOI
  102. Tarín-Pelló, 2022, Antibiotic resistant bacteria: current situation and treatment options to accelerate the development of a new antimicrobial arsenal, Expert Rev. Anti-Infect. Ther., 20, 1095, 10.1080/14787210.2022.2078308 · DOI · Paper page
  103. Teng, 2023, Combatting resistance: understanding multi-drug resistant pathogens in intensive care units, Biomed. Pharmacother., 167, 10.1016/j.biopha.2023.115564 · DOI
  104. Theuretzbacher, 2020, The global preclinical antibacterial pipeline, Nat. Rev. Microbiol., 18, 275, 10.1038/s41579-019-0288-0 · DOI · Paper page
  105. Vacca, 2022, Monoclonal antibodies for bacterial pathogens: mechanisms of action and engineering approaches for enhanced effector functions, Biomedicines, 10, 2126, 10.3390/biomedicines10092126 · DOI
  106. Visca, 2019, The antimetabolite 3-bromopyruvate selectively inhibits Staphylococcus aureus, Int. J. Antimicrob. Agents, 53, 449, 10.1016/j.ijantimicag.2018.11.008 · DOI
  107. Wang, 2021, Antimicrobial peptides towards clinical application: delivery and formulation, Adv. Drug Deliv. Rev., 175, 10.1016/j.addr.2021.05.028 · DOI · Paper page
  108. Wang, 2020, Defeating antibiotic-resistant bacteria: exploring alternative therapies for a post-antibiotic era, Int. J. Mol. Sci., 21, 1061, 10.3390/ijms21031061 · DOI · Paper page
  109. Wang, 2022, Infection microenvironment-related antibacterial nanotherapeutic strategies, Biomaterials, 280, 10.1016/j.biomaterials.2021.121249 · DOI · Paper page
  110. Wang, 2020, CRISPR/cas systems redefine nucleic acid detection: principles and methods, Biosens. Bioelectron., 165, 10.1016/j.bios.2020.112430 · DOI · Paper page
  111. Wright, 1992, D-Alanyl-D-alanine ligases and the molecular mechanism of vancomycin resistance, Acc. Chem. Res., 25, 468, 10.1021/ar00022a006 · DOI · Paper page
  112. Wu, 2024, Hyaluronic acid-decorated curcumin-based coordination nanomedicine for enhancing the infected diabetic wound healing, Int. J. Biol. Macromol., 263, 10.1016/j.ijbiomac.2024.130249 · DOI
  113. Wurpts, 2019, Allergo J. Int., 28, 121, 10.1007/s40629-019-0100-8 · DOI
  114. Xiong, 2014, Delivery of antibiotics with polymeric particles, Adv. Drug Deliv. Rev., 78, 63, 10.1016/j.addr.2014.02.002 · DOI · Paper page
  115. Yamazaki, 2024, The role of Staphylococcus aureus quorum sensing in cutaneous and systemic infections, Inflamm. Regen., 44, 9, 10.1186/s41232-024-00323-8 · DOI
  116. Yedavally, 2023, Opportunities to apply nanomedicine in the treatment of Staphylococcus aureus infections, Invest. Staphylococcus aureus Intracell. Tactics Nanomed. Solut., 33
  117. Zhanel, 2012, Oritavancin: mechanism of action, Clin. Infect. Dis., 54, S214, 10.1093/cid/cir920 · DOI · Paper page
  118. Zhanel, 2009, Ceftaroline: a novel broad-spectrum cephalosporin with activity against meticillin-resistant Staphylococcus aureus.", Drugs, 69, 809, 10.2165/00003495-200969070-00003 · DOI
  119. Zhang, X., M.H. Marichannegowda, K.P. Rakesh and H.-L.J.M. r Qin 2018. "Master mechanisms of Staphylococcus aureus: consider its excellent protective mechanisms hindering vaccine development!" 212: 59-66. · DOI · Paper page
  120. Zhang, X., K. Rakesh, S.N.A. Bukhari, M. Balakrishna, H. Manukumar and H.-L.J.B.C. Qin 2018. "Multi-targetable chalcone analogs to treat deadly Alzheimer’s disease: Current view and upcoming advice." 80: 86-93. · DOI
  121. Zhang, X., H. Manukumar, K. Rakesh, C. Karthik, H.N. Prasad, S.N. Swamy, P. Mallu, Y.H. E. Mohammed and H.-L.J. M. p Qin (2018). "Role of BP* C@ AgNPs in Bap-dependent multicellular behavior of clinically important methicillin-resistant Staphylococcus aureus (MRSA) biofilm adherence: a key virulence study." 123: 275-284. · DOI · Paper page
  122. Zharkova, 2019, Application of antimicrobial peptides of the innate immune system in combination with conventional antibiotics—a novel way to combat antibiotic resistance?, Front. Cell. Infect. Microbiol., 9, 128, 10.3389/fcimb.2019.00128 · DOI · Paper page

Cited by

See all 68

Metadata

Authors
Kumar, S., Mahato, R. P., Ch, S., & Kumbham, S.
Venue
The Microbe
Publisher
Elsevier BV
Published
2025-03
Volume
6
Pages
100281
ISSN
2950-1946
Cited by
68
References
7
Language
en
Update notices
erratum (2025-09-01)
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Current strategies against multidrug-resistant Staphylococcus aureus and advances toward future therapy. https://app.cochat.ai/papers/10.1016/j.microb.2025.100281
The paper
Kumar, S., Mahato, R. P., Ch, S., & Kumbham, S. (2025). Current strategies against multidrug-resistant Staphylococcus aureus and advances toward future therapy. The Microbe. https://doi.org/10.1016/j.microb.2025.100281

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.